CathVision secures $9M for its ECGenius System and CARDIALYTICS AI-Suite

The financing will help advance commercial operations driving adoption of the ECGenius System, the company's innovative EP recording technology, and support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with unprecedented levels of automated analysis during cardiac ablation procedures. This includes expansion of the company's sales team and U.S. presence, and further development of the CARDIALYTICS suite of artificial intelligence-powered analytics. This newest round of funding brings the total raised to date by CathVision to nearly $30 million.

Funding 💰

Round $9M

Quotes 💬

Despite challenging times in the financial markets, CathVision remains a confident investment for stakeholders because we are achieving critical milestones that validate the need for our technology, revenue generation through successful commercialization, and our commitment to ongoing R&D. This investment round will support the acceleration of commercial adoption through 2024 as we position CathVision to significantly impact how, throughout the United States, we help physicians treat cardiac arrhythmias more effectively.
Mads Matthiesen, CEO of CathVision

About 🏢

CathVision is developing electrophysiology solutions centered around an innovative EP recording system and AI algorithm platform - the ECGenius System. The ECGenius System is an innovative EP recording technology that includes a proprietary hardware amplifier allowing electrophysiologists to acquire high-fidelity, low-noise cardiac electrograms to improve the diagnosis and treatment of complex atrial arrhythmias such as atrial fibrillation (AF). Using this system, CathVision is empowering physicians to make more informed clinical decisions in the EP lab. In addition to its headquarters in Denmark, the company has an office in Minnesota. more